Pulmonary Hypertension Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People of any age are welcome to participate.
- You must be willing and able to give written consent to take part in the study.
- You must have been diagnosed with pulmonary hypertension (high blood pressure in the lungs), which can include several types: the form with no known cause (idiopathic), the form linked to connective tissue diseases (such as lupus or scleroderma), the form linked to congenital heart defects, the form linked to HIV infection, the form linked to liver disease, the form caused by old blood clots in the lungs, the form caused by left-sided heart problems, or the form caused by lung diseases such as COPD or lung scarring.
- You may also qualify if you have a related condition called "relative pulmonary hypertension" linked to a specific type of heart surgery (cavopulmonary anastomosis or Fontan-type surgery), even if your blood pressure does not meet the usual technical definition of pulmonary hypertension (confirm with trial site).
- You must have recently started a specific type of medication for pulmonary hypertension (from one of these drug groups: endothelin receptor antagonists, PDE-5 inhibitors, soluble guanylate cyclase stimulators, or prostacyclins) within the last 3 months, either alone or in combination.
- If you have pulmonary hypertension linked to a congenital heart defect, you may be eligible whether you are just starting treatment or have already been on treatment for longer, including those with severe disease (such as Eisenmenger syndrome).
Who may not be able to join:
- People who have already been taking any of the specific pulmonary hypertension medications listed above for more than 3 months before entering the study are generally not eligible — unless they have pulmonary hypertension linked to a congenital heart defect, in which case this rule does not apply.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Marius M Hoeper, MD, PhD, Department of Pulmonology, Medical School Hannover, Germany
Phone: +498152
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Number of patients on monotherapy vs combination therapies at baseline and during follow-up (drug utilisation patterns)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.